Tokyo, June 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061746) titled 'HR of PFS as surrogate endpoints for HR of OS in RCTs of systemic immuno-therapies for advanced, locally advanced, and relapsed NSCLC' on May 30.
Study Type:
Others,meta-analysis etc
Primary Sponsor:
Institute - Yokohama City University Hospital
Condition:
Condition - advanced, locally advanced, and relapsed NSCLC
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - Although OS is universally recognized as the gold-standard endpoint in oncology clinical trials due to its direct clinical benefit to patients and objective, bias-free measurement, evaluating it has beco...